Tivic gets approved for ncVNS optimization study, readies for enrollment

Tivic Health Systems announced that it has received approval from The Feinstein Institutes’ Institutional Review Board for the next phase of clinical work on its non-invasive cervical vagus nerve stimulation or ncVNS, approach. This clinical research collaboration with Feinstein is designed to advance the development of Tivic Health’s ncVNS technology by refining and optimizing stimulation parameters. Physiological measurements will be used to enhance device performance and refine specifications such as electrode positioning and electrical waveform parameters. The data derived from the study will be used to inform the selection of clinical populations of interest and help shape the clinical study design for upcoming trials. The company has previously announced the successful completion of its Phase 1 study on ncVNS. Key goals of the current study include: Optimizing Treatment Strategies: The research will provide critical data to advance both personalization of treatment and … The company has also recently announced its collaboration with Fletcher Spaght, a leading healthcare growth strategy firm. Fletcher Spaght has begun substantiating clinical applications with high unmet needs that have potential to be addressed by Tivic Health’s patent-pending ncVNS system…